 SAN DIEGO, Nov. 1, 2021 PRNewswire -- Inhibrx, Inc. Nasdaq: INBX, a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced today that the Company will be presenting at the Connective Tissue Oncology Society, or CTOS, 2021 Virtual Annual Meeting taking place November 10-13, 2021. CTOS Virtual Presentation Details: Title: Safety and Efficacy of the Tetravalent Death Receptor 5 Agonist INBRX-109 in Patients with Conventional Chondrosarcoma: Update from the Phase 1 Expansion CohortLead Author: Vivek Subbiah, MDAbstract: 1082377, P 018Oral Presentation on Thursday, November 11th at 1:29 p.m. 